ReviewCureus2026
Recent Advances in the Management of IgA Nephropathy: From Supportive Care to Targeted Therapies.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A nephropathy (IgAN) represents the predominant glomerulonephritis globally and is a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD). Historically, supportive management, with blood pressure control, renal angiotensin system (RAS) blockade, and active management with steroids, has been tried. However, the treatment landscape has recently become more complex with the introduction of several highly specific therapies. This review aims to provide an in-depth overview of the latest developments in IgAN management, including traditional supportive care and exposure to novel and specific treatments. The review highlights the morbidity of IgAN, its risk of progression to ESRD, and the importance of supportive care. New supportive treatments, such as sodium-glucose cotransporter-2 (SGLT2) inhibitors and sparsentan, demonstrate renal protective effects. As for active management, corticosteroids remain effective but are constrained by their side effects. New specific agents, such as budesonide, complement inhibitors, and immune modulators, are showing potential effectiveness in improving proteinuria and preserving renal function. Nonetheless, it faces certain challenges, including a lack of head-to-head trials, limited long-term efficacy and safety data, and affordability issues. The development of IgAN management has considerable potential, although additional research and the implementation of these findings are crucial to optimizing outcomes for patients worldwide.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.